<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03314974</url>
  </required_header>
  <id_info>
    <org_study_id>2015LS034</org_study_id>
    <secondary_id>MT2015-29</secondary_id>
    <nct_id>NCT03314974</nct_id>
  </id_info>
  <brief_title>Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders</brief_title>
  <official_title>Myeloablative Allogeneic Hematopoietic Cell Transplantation Using a Related or Unrelated Donor for the Treatment of Hematological Diseases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Masonic Cancer Center, University of Minnesota</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Masonic Cancer Center, University of Minnesota</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase II study of allogeneic hematopoietic stem cell transplant (HCT) using a&#xD;
      myeloablative preparative regimen (of either total body irradiation (TBI); or,&#xD;
      fludarabine/busulfan for patients unable to receive further radiation). followed by a&#xD;
      post-transplant graft-versus-host disease (GVHD) prophylaxis regimen of post-transplant&#xD;
      cyclophosphamide (PTCy), tacrolimus (Tac), and mycophenolate mofetil (MMF).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 30, 2018</start_date>
  <completion_date type="Anticipated">November 10, 2025</completion_date>
  <primary_completion_date type="Anticipated">January 10, 2025</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Chronic GVHD - 1 year</measure>
    <time_frame>1 year</time_frame>
    <description>Incidence of chronic GVHD</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Grade II-IV acute GVHD</measure>
    <time_frame>Day +100</time_frame>
    <description>Cumulative incidence grade II-IV acute GVHD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chronic GVHD - 2 years</measure>
    <time_frame>2 years</time_frame>
    <description>Incidence of chronic GVHD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse</measure>
    <time_frame>2 years</time_frame>
    <description>Cumulative incidence of relapse</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>2 years</time_frame>
    <description>Cumulative incidence of overall survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment-related mortality</measure>
    <time_frame>2 years</time_frame>
    <description>Cumulative incidence of treatment-related mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Graft-versus-host disease-free, relapse free survival (GRFS)</measure>
    <time_frame>1 year</time_frame>
    <description>Cumulative incidence of GRFS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Graft-versus-host disease-free, relapse free survival (GRFS)</measure>
    <time_frame>2 years</time_frame>
    <description>Cumulative incidence of GRFS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neutrophil Engraftment</measure>
    <time_frame>Day 42</time_frame>
    <description>Cumulative incidence of Neutrophil Engraftment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neutrophil Engraftment</measure>
    <time_frame>6 months</time_frame>
    <description>Cumulative incidence of Neutrophil Engraftment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Platelet Engraftment</measure>
    <time_frame>Day 42</time_frame>
    <description>Cumulative incidence of Platelet Engraftment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Platelet Engraftment</measure>
    <time_frame>6 months</time_frame>
    <description>Cumulative incidence of Platelet Engraftment</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Acute Leukemia</condition>
  <condition>Acute Myeloid Leukemia</condition>
  <condition>Acute Lymphoblastic Leukemia</condition>
  <condition>Lymphoma</condition>
  <condition>Chronic Myelogenous Leukemia</condition>
  <condition>Plasma Cell Leukemia</condition>
  <condition>Myeloproliferative Neoplasms</condition>
  <condition>Myelofibrosis</condition>
  <condition>Myelodysplasia</condition>
  <condition>Refractory Anemia</condition>
  <condition>High Risk Anemia</condition>
  <condition>Chronic Lymphocytic Leukemia</condition>
  <condition>Small Lymphocytic Lymphoma</condition>
  <condition>Marginal Zone B-Cell Lymphoma</condition>
  <condition>Follicular Lymphoma</condition>
  <condition>Lymphoplasmacytic Lymphoma</condition>
  <condition>Mantle-Cell Lymphoma</condition>
  <condition>Prolymphocytic Leukemia</condition>
  <condition>Diffuse Large Cell Non Hodgkins Lymphoma</condition>
  <condition>Lymphoblastic Lymphoma</condition>
  <condition>Burkitt Lymphoma</condition>
  <condition>High Grade Non-Hodgkin's Lymphoma, Adult</condition>
  <condition>Multiple Myeloma</condition>
  <condition>Juvenile Myelomonocytic Leukemia</condition>
  <condition>Biphenotypic/Undifferentiated/Prolymphocytic Leukemias</condition>
  <condition>MRD Positive Leukemia</condition>
  <condition>Natural Killer Cell Malignancies</condition>
  <condition>Acquired Bone Marrow Failure Syndromes</condition>
  <arm_group>
    <arm_group_label>TBI Regimen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-TBI Regimen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>HSCT with TBI Regimen</intervention_name>
    <description>Day -5 to -2: Total Body Irradiation Day 0: Hematopoietic Stem Cell Transplantation Day +3 to +4: Cyclophosphamide Day +5: Tacrolimus from day +5 until taper day +100 (day +60 for peds if no acute or chronic GVHD present) Day +5: Mycophenolate mofetil through day +35 or 7 days after engraftment, whichever day is later, if no acute GVHD</description>
    <arm_group_label>TBI Regimen</arm_group_label>
    <other_name>Hematopoietic Stem Cell Transplantation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>HSCT with Non-TBI Regimen</intervention_name>
    <description>Day -5 to Day -2: Busulfan and Fludaribine Day 0: Hematopoietic Stem Cell Transplantation Day +3 to +4: Cyclophosphamide Day +5: Tacrolimus from day +5 until taper day +100 (day +60 for peds if no acute or chronic GVHD present) Day +5: Mycophenolate mofetil through day +35 or 7 days after engraftment, whichever day is later, if no acute GVHD</description>
    <arm_group_label>Non-TBI Regimen</arm_group_label>
    <other_name>Hematopoietic Stem Cell Transplantation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -Inclusion Criteria:&#xD;
&#xD;
          -  Age: ≤ 60 years of age&#xD;
&#xD;
          -  Performance Status: Karnofsky ≥ 80%, Lansky play score ≥ 70&#xD;
&#xD;
          -  Consent: Voluntary written consent (adult or legally authorized representative; or&#xD;
             parental/guardian)&#xD;
&#xD;
          -  Adequate Organ Function:&#xD;
&#xD;
               -  Renal: Creatinine &lt;2x upper limit of normal. Patients above this limit must have&#xD;
                  creatinine clearance ≥ 40 ml/min/1.73m2 as determined by an age-appropriate&#xD;
                  method, such as cystatin C GFR.&#xD;
&#xD;
               -  Hepatic: Bilirubin, AST, alkaline phosphatase &lt;4 times the upper limit of&#xD;
                  institutional normal&#xD;
&#xD;
               -  Pulmonary: Diffusion capacity of oxygen, corrected for hemoglobin, &gt; 50% of&#xD;
                  predicted. For pediatric patients not able to undergo PFTs or diffusion testing:&#xD;
                  O2 sat of &gt;95% on room air&#xD;
&#xD;
               -  Cardiac: Absence of decompensated congestive heart failure, or uncontrolled&#xD;
                  arrhythmia and left ventricular ejection fraction &gt; 45%. For children not able to&#xD;
                  cooperate with MUGA or echocardiography, such should be clearly stated in the&#xD;
                  physician's documentation&#xD;
&#xD;
               -  HIV Status: HIV infection with undetectable viral load. All HIV+ patients must be&#xD;
                  evaluated by Infectious Disease (ID) and a HIV management plan establish prior to&#xD;
                  transplantation&#xD;
&#xD;
        Other Inclusion Criteria:&#xD;
&#xD;
          -  Women of child bearing potential and sexually active males with partners of child&#xD;
             bearing potential must agree to use adequate birth control for the duration of&#xD;
             treatment.&#xD;
&#xD;
          -  Donor Availability: Patients considered for transplantation must have a sufficient&#xD;
             graft as based on current criteria of the University of Minnesota Blood and Marrow&#xD;
             Transplantation Program&#xD;
&#xD;
          -  Eligible Diseases and Status: Patients are eligible unless their treatment is to be&#xD;
             guided by a higher priority protocol.&#xD;
&#xD;
          -  Acute Leukemias: Must be in remission by morphology (≤5% blasts). Also a small&#xD;
             percentage of blasts that is equivocal between marrow regeneration vs. early relapse&#xD;
             are acceptable provided there are no associated cytogenetic markers consistent with&#xD;
             relapse.&#xD;
&#xD;
          -  Acute Myeloid Leukemia (AML) and related precursor neoplasms: 2nd or greater complete&#xD;
             remission (CR); first complete remission (CR1) in patients &gt; 60 years old; CR1 in ≤ 60&#xD;
             years old that is NOT considered as favorable-risk.&#xD;
&#xD;
          -  Favorable risk AML is defined as having one of the following:&#xD;
&#xD;
               -  t(8,21) without cKIT mutation&#xD;
&#xD;
               -  inv(16) or t(16;16) without cKIT mutation&#xD;
&#xD;
               -  Normal karyotype with mutated NPM1 and wild type FLT-ITD&#xD;
&#xD;
               -  Normal karyotype with double mutated CEBPA&#xD;
&#xD;
               -  Acute prolymphocytic leukemia (APL) in first molecular remission at the end of&#xD;
                  consolidation&#xD;
&#xD;
          -  Very high risk pediatric patients with AML: Patients &lt;21 years, however, are eligible&#xD;
             with (M2 marrow) with &lt; 25% blasts in marrow after having failed one or more cycles of&#xD;
             chemotherapy.&#xD;
&#xD;
          -  Acute lymphoblastic leukemia (ALL)/lymphoma: second or greater CR; CR1 unable to&#xD;
             tolerate consolidation chemotherapy due to chemotherapy-related toxicities; CR1&#xD;
             high-risk ALL.&#xD;
&#xD;
          -  High risk ALL is defined as having one of the following:&#xD;
&#xD;
               -  Evidence of high risk cytogenetics, e.g. t(9;22), t(1;19), t(4;11), other MLL&#xD;
                  rearrangements, IKZF1&#xD;
&#xD;
               -  30 years of age or older at diagnosis&#xD;
&#xD;
               -  White blood cell counts of greater than 30,000/mcL (B-ALL) or greater than&#xD;
                  100,000/mcL (T-ALL) at diagnosis&#xD;
&#xD;
               -  CNS leukemia involvement during the course of disease&#xD;
&#xD;
               -  Slow cytologic response (&gt;10% lymphoblasts in bone marrow on Day 14 of induction&#xD;
                  therapy)&#xD;
&#xD;
               -  Evidence of persistent immonophenotypic or molecular minimal residual disease&#xD;
                  (MRD) at the end of induction and consolidation therapy&#xD;
&#xD;
          -  Very high risk pediatric patients with ALL: patients &lt;21 years are also considered&#xD;
             high risk CR1 if they had M2 or M3 marrow at day 42 from the initiation of induction&#xD;
             or M3 marrow at the end of induction. They are eligible once they achieve a complete&#xD;
             remission.&#xD;
&#xD;
          -  Chronic Myelogenous Leukemia excluding refractory blast crisis: To be eligible in&#xD;
             first chronic phase (CP1) patient must have failed or be intolerant to one or more&#xD;
             tyrosine kinase inhibitors.&#xD;
&#xD;
          -  Plasma Cell Leukemia after initial therapy, in patients who have achieved at least a&#xD;
             partial remission&#xD;
&#xD;
          -  Myeloproliferative Neoplasms/Myelofibrosis, either primary as a result of polycythemia&#xD;
             vera or essential thrombocythemia, with disease risk of intermediate or high-risk&#xD;
             according to DIPSS criteria. Blasts must be &lt;10% by bone marrow aspirate morphology.&#xD;
&#xD;
          -  Myelodysplasia (MDS) IPSS INT-2 or High Risk (i.e. RAEB, RAEBt) or Refractory Anemia&#xD;
             with severe pancytopenia, transfusion dependence, or high risk cytogenetics or&#xD;
             molecular features. Blasts must be &lt; 10% by a representative bone marrow aspirate&#xD;
             morphology.&#xD;
&#xD;
          -  Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Marginal Zone&#xD;
             B-Cell Lymphoma or Follicular Lymphoma are eligible if there was disease&#xD;
             progression/relapse within 12 of achieving a partial or complete remission. Patients&#xD;
             who had remissions lasting &gt; 12 months, are eligible after at least two prior&#xD;
             therapies. Patients with bulky disease (nodal mass greater than 5 cm) should be&#xD;
             considered for debulking chemotherapy before transplant.&#xD;
&#xD;
          -  Lymphoplasmacytic Lymphoma, Mantle-Cell Lymphoma, Prolymphocytic Leukemia are eligible&#xD;
             after initial therapy in CR1+ or PR1+.&#xD;
&#xD;
          -  Diffuse large Cell NHL &gt; CR/&gt; PR: Patients in CR/PR with initial short remission (&lt;6&#xD;
             months) are eligible, or those who have failed/or are not eligible for autologous&#xD;
             transplant.&#xD;
&#xD;
          -  Lymphoblastic Lymphoma, Burkitt's Lymphoma, and other high-grade NHL after initial&#xD;
             therapy if stage III/IV in CR1/PR1 or after progression if stage I/II &lt; 1 year.&#xD;
&#xD;
          -  Multiple Myeloma beyond PR2: Patients with chromosome 13 abnormalities, first response&#xD;
             lasting less than 6 months, or β-2 microglobulin &gt; 3 mg/L, may be considered for this&#xD;
             protocol after initial therapy.&#xD;
&#xD;
          -  Juvenile myelomonocytic leukemia&#xD;
&#xD;
          -  Biphenotypic/Undifferentiated/Prolymphocytic Leukemias in first or subsequent CR.&#xD;
&#xD;
          -  MRD positive leukemia (AML, ALL or accelerated/blast phase CML). Selected patients in&#xD;
             morphologic CR, but with positive immunophenotypic (flow cytometry) or molecular&#xD;
             evidence of MRD may be eligible if recent chemotherapy has not resulted in MRD&#xD;
             negative status.&#xD;
&#xD;
          -  Natural Killer Cell Malignancies&#xD;
&#xD;
          -  Acquired Bone Marrow Failure Syndromes except for Fanconi Anemia or Dyskeratosis&#xD;
             Congenita&#xD;
&#xD;
          -  Other Leukemia Subtypes: A major effort in the field of hematology is to identify&#xD;
             patients who are of high risk for treatment failure so that patients can be&#xD;
             appropriately stratified to either more (or less) intensive therapy. This effort is&#xD;
             continually ongoing and retrospective studies identify new disease features or&#xD;
             characteristics that are associated with treatment outcomes. Therefore, if new&#xD;
             features are identified after the writing of this protocol, patients can be enrolled&#xD;
             with the approval of two members of the study committee.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Chemotherapy refractory large cell and high grade NHL (i.e., progressive disease after&#xD;
             &gt; 2 salvage regimens)&#xD;
&#xD;
          -  CML in blast crisis&#xD;
&#xD;
          -  Large cell lymphoma, mantle cell lymphoma and Hodgkin disease that is progressing on&#xD;
             salvage therapy.&#xD;
&#xD;
          -  Evidence of progressive disease by imaging modalities or biopsy - persistent PET&#xD;
             activity, though possibly related to lymphoma, is not an exclusion criterion in the&#xD;
             absence of CT changes indicating progression.&#xD;
&#xD;
          -  Active central nervous system malignancy&#xD;
&#xD;
          -  if ≤ 18 years old, prior myeloablative transplant within the last 6 months. If &gt;18&#xD;
             years old prior myeloablative allotransplant or autologous transplant&#xD;
&#xD;
          -  Active HIV infection or known HIV positive serology&#xD;
&#xD;
          -  active uncontrolled infection&#xD;
&#xD;
          -  Pregnant or breastfeeding. The agents used in this study include Pregnancy Category D:&#xD;
             known to cause harm to a fetus. Females of childbearing potential must have a negative&#xD;
             pregnancy test prior to starting therapy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shernan Holtan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Masonic Cancer Center, University of Minnesota</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tamy Grainger</last_name>
    <phone>(612)-273-2800</phone>
    <email>tgraing1@fairview.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Masonic Cancer Center at University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55337</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tamy Grainger, RN</last_name>
      <phone>612-273-2800</phone>
      <email>tgraing1@fairview.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>October 16, 2017</study_first_submitted>
  <study_first_submitted_qc>October 16, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 19, 2017</study_first_posted>
  <last_update_submitted>May 21, 2021</last_update_submitted>
  <last_update_submitted_qc>May 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>AML</keyword>
  <keyword>ALL</keyword>
  <keyword>MDS</keyword>
  <keyword>NHL</keyword>
  <keyword>CLL</keyword>
  <keyword>CML</keyword>
  <keyword>SLL</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Burkitt Lymphoma</mesh_term>
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Mantle-Cell</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
    <mesh_term>Lymphoma, B-Cell, Marginal Zone</mesh_term>
    <mesh_term>Leukemia, Prolymphocytic</mesh_term>
    <mesh_term>Leukemia, Myelomonocytic, Juvenile</mesh_term>
    <mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
    <mesh_term>Leukemia, Plasma Cell</mesh_term>
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Myeloproliferative Disorders</mesh_term>
    <mesh_term>Anemia, Refractory</mesh_term>
    <mesh_term>Bone Marrow Failure Disorders</mesh_term>
    <mesh_term>Pancytopenia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

